Literature DB >> 30348485

Reduced nasal nitric oxide levels in patients with eosinophilic chronic rhinosinusitis.

Kanako Yoshida1, Tetsuji Takabayashi2, Yoshimasa Imoto1, Masafumi Sakashita1, Norihiko Narita1, Shigeharu Fujieda1.   

Abstract

BACKGROUND: In Eosinophilic chronic rhinosinusitis (ECRS), it is difficult to estimate the refractoriness and recurrence risk for each patient. Fraction of exhaled nitric oxide (FeNO) is known as a biomarker of eosinophilic inflammation in lower airway. It has been reported that nasal NO has some crucial functions in the upper and lower airways. However, in upper airway, paranasal sinuses, the usefulness of NO measurement remains controversial. The purpose of this study is to identify the usefulness of nasal NO measurement in ECRS and the involvement of nasal NO in the pathogenesis of ECRS.
METHODS: We compared the nasal NO levels of ECRS, non-ECRS, and normal control groups. Correlation between nasal NO levels and clinical findings were observed. Then, we compared nasal NO levels before and after endoscopic sinus surgery (ESS). We also examine whether nasal NO levels might discriminate ECRS by the receiver operating characteristic (ROC) curve analysis.
RESULTS: Nasal NO levels were significantly decreased in ECRS compared to the other two groups. Moreover, nasal NO levels in ECRS significantly and negatively correlated with eosinophil levels and CT score. However, they did not correlate with the nasal polyp score. Nasal NO levels were not upregulated soon after opening the sinus ostium by ESS. The ROC curves for nasal NO levels were used to discriminate all CRS patients and ECRS patients from normal controls.
CONCLUSIONS: Nasal NO may be useful as a marker of ECRS severity and low nasal NO levels in ECRS may contribute to its pathogenesis.
Copyright © 2018 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Asthma; Chronic rhinosinusitis; Eosinophilic chronic rhinosinusitis; Eosinophilic inflammation; Nasal nitric oxide level

Mesh:

Substances:

Year:  2018        PMID: 30348485     DOI: 10.1016/j.alit.2018.09.005

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  6 in total

1.  Nasal Nitric Oxide in Primary Immunodeficiency and Primary Ciliary Dyskinesia: Helping to Distinguish Between Clinically Similar Diseases.

Authors:  Zofia N Zysman-Colman; Kimberley R Kaspy; Reza Alizadehfar; Keith R NyKamp; Maimoona A Zariwala; Michael R Knowles; Donald C Vinh; Adam J Shapiro
Journal:  J Clin Immunol       Date:  2019-03-26       Impact factor: 8.317

Review 2.  Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin.

Authors:  Tetsuji Takabayashi; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2020-03       Impact factor: 10.793

3.  Systematic review and meta-analysis of the curative effects and safety of endoscopic sinus surgery in children with chronic sinusitis with nasal polyps.

Authors:  Jingqiong Zheng; Lingyan Yu; Wenhui Hu; Yijian Yu
Journal:  Transl Pediatr       Date:  2022-07

4.  Clinical and Laboratory Features of Various Criteria of Eosinophilic Chronic Rhinosinusitis: A Systematic Review and Meta-Analysis.

Authors:  Do Hyun Kim; Sung Won Kim; Mohammed Abdullah Basurrah; Se Hwan Hwang
Journal:  Clin Exp Otorhinolaryngol       Date:  2022-04-08       Impact factor: 3.340

Review 5.  Nasal Nitric Oxide in Chronic Rhinosinusitis with or without Nasal Polyps: A Systematic Review with Meta-Analysis.

Authors:  Pasquale Ambrosino; Antonio Molino; Giorgio Alfredo Spedicato; Paolo Parrella; Roberto Formisano; Andrea Motta; Matteo Nicola Dario Di Minno; Mauro Maniscalco
Journal:  J Clin Med       Date:  2020-01-11       Impact factor: 4.241

6.  Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).

Authors:  Enrico Heffler; Giovanna Elisiana Carpagnano; Elisabetta Favero; Giuseppe Guida; Mauro Maniscalco; Andrea Motta; Giovanni Paoletti; Giovanni Rolla; Eugenio Baraldi; Vincenza Pezzella; Giorgio Piacentini; Stefano Nardini
Journal:  Multidiscip Respir Med       Date:  2020-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.